NWRN Stock Overview
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Newron Pharmaceuticals S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 7.77 |
| 52 Week High | CHF 11.20 |
| 52 Week Low | CHF 5.20 |
| Beta | 0.59 |
| 1 Month Change | 20.28% |
| 3 Month Change | -27.11% |
| 1 Year Change | -22.92% |
| 3 Year Change | 463.04% |
| 5 Year Change | 313.30% |
| Change since IPO | -85.37% |
Recent News & Updates
Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts
Apr 05
Take Care Before Jumping Onto Newron Pharmaceuticals S.p.A. (VTX:NWRN) Even Though It's 29% Cheaper
Apr 03Recent updates
Earnings Miss: Newron Pharmaceuticals S.p.A. Missed EPS By 53% And Analysts Are Revising Their Forecasts
Apr 05Take Care Before Jumping Onto Newron Pharmaceuticals S.p.A. (VTX:NWRN) Even Though It's 29% Cheaper
Apr 03Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) Price In Tune With Revenues
Sep 03Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being
Apr 11We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt
Nov 06Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package
Apr 06Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?
Apr 01A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns
Feb 25Shareholder Returns
| NWRN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -4.9% | 2.8% | 2.0% |
| 1Y | -22.9% | 7.7% | 3.4% |
Return vs Industry: NWRN underperformed the Swiss Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: NWRN underperformed the Swiss Market which returned 2.7% over the past year.
Price Volatility
| NWRN volatility | |
|---|---|
| NWRN Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in CH Market | 9.3% |
| 10% least volatile stocks in CH Market | 2.5% |
Stable Share Price: NWRN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: NWRN's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 22 | Stefan Weber | www.newron.com |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
Newron Pharmaceuticals S.p.A. Fundamentals Summary
| NWRN fundamental statistics | |
|---|---|
| Market cap | CHF 155.10m |
| Earnings (TTM) | CHF 14.83m |
| Revenue (TTM) | CHF 48.09m |
Is NWRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NWRN income statement (TTM) | |
|---|---|
| Revenue | €51.39m |
| Cost of Revenue | €0 |
| Gross Profit | €51.39m |
| Other Expenses | €35.55m |
| Earnings | €15.84m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Sep 16, 2025
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 100.00% |
| Net Profit Margin | 30.83% |
| Debt/Equity Ratio | 3,405.8% |
How did NWRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 02:32 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Newron Pharmaceuticals S.p.A. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Bob Pooler | Bank am Bellevue |
| Maria Maldonado | Bank Vontobel AG |